A developer of novel robotic solutions for unmet medical needs for microsurgery. MMI has developed the first teleoperated robotic platform for suturing in open surgery with wristed microinstruments. It offers the surgeon motion scaling and tremor elimination and aims to facilitate existing procedures as well as enable new ones in the domain of microsurgery, from post-oncological and trauma reconstructions to ophthalmology, organ transplantation and pediatric surgery.
We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. Our Symani Surgical System is proof of what’s possible when a purpose-driven team is relentlessly committed to meaningful innovation. Our groundbreaking technology-enabled approach to microsurgery and supermicrosurgery can put better outcomes within reach.
Total Funding: $227M
Funding Stage: Series C
Business Stage: Scaling Up
Market: B2B
Company Size: 101 to 250
Founded: 2011
Feb 2024
- Funding : MMI raised $110M Series C round. Total funding reached to $227M
Jan 2024
- MMI and ab medica Partner to Expand Access to Symani® Surgical System
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at MMI (Medical Micro)
Mark Toland
Chief Executive Officer
